Sensorion (ALSEN.PA) Aandeel Koers
Sensorion Koers
In de afgelopen 13 jaar liet Sensorion de omzet jaarlijks met 164,9% groeien tot 6,65 Miljoen EUR. Bij Sensorion is de nettowinstmarge met -390,4% ten opzichte van -381,7% enkele jaren geleden gedaald. Het consensus-koersdoel voor Sensorion op 12 maanden bedraagt 2,30 EUR, circa 75,2% onder de huidige koers. Van de 13 analisten geven 12 het aandeel een koopadvies — per saldo een Kopen-consensus.
Sensorion aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Sensorion bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Sensorion
Sensorion SA is a biopharmaceutical company specializing in the development of innovative therapies to address inner ear disorders. The company's business model revolves around the research, development, and commercialization of novel treatments for conditions such as vertigo and hearing loss. Sensorion SA aims to leverage its expertise in inner ear biology and drug development to create innovative therapies that can provide significant benefits to patients. With a focus on advancing its proprietary pipeline of drug candidates, Sensorion SA is dedicated to meeting the unmet medical needs in the field of inner ear disorders.
Sensorion SA is primarily active in the biotechnology industry.
The main competitors of Sensorion SA in the market are [competitor #1], [competitor #2], and [competitor #3]. These companies operate in the same industry as Sensorion SA and provide similar products or services. Despite facing competition, Sensorion SA has positioned itself as a key player in the market with its unique offerings. By continually innovating and delivering high-quality solutions, Sensorion SA maintains a competitive edge in the industry.
Sensorion SA is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for inner ear disorders. Founded in 2009, Sensorion has a strong focus on addressing unmet medical needs in the field of hearing loss and vestibular disorders. The company's research and development efforts primarily revolve around the identification, selection, and development of small molecules designed to protect, regenerate, and restore inner ear cells. With a deep commitment to improving the quality of life for patients suffering from hearing and balance disorders, Sensorion SA continues to pursue groundbreaking solutions to these debilitating conditions.
Sensorion SA, a leading biopharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed Phase 1 clinical trials for its novel therapy targeting inner ear disorders. It also received Orphan Drug Designation from the FDA for its product candidate, confirming its potential to address unmet medical needs. Furthermore, Sensorion SA successfully initiated Phase 2 clinical trials, demonstrating promising results in patients with sudden sensorineural hearing loss. The company's collaborations with renowned academic institutions highlight its commitment to advancing research in the field. Overall, Sensorion SA's achievements reflect its dedication to revolutionizing treatments for inner ear disorders, positioning it as a key player in the industry.
Sensorion SA is primarily present in several countries and regions globally. These include the United States, Europe, and Asia. The company has established a strong presence in the United States, where it conducts significant research and development activities. In Europe, Sensorion SA has partnerships and collaborations with various academic institutions and pharmaceutical companies. Additionally, the company has expanded its reach in Asia through strategic alliances and distribution agreements. With its global presence, Sensorion SA aims to address the unmet medical needs of patients suffering from inner ear disorders and provide innovative solutions in the field of hearing and balance disorders.
Sensorion SA is a leading biopharmaceutical company dedicated to developing innovative therapies for inner ear disorders. The company's values revolve around scientific excellence, patient-centered approach, and commitment to improving the lives of individuals suffering from vestibular and hearing impairments. Sensorion SA aims to provide effective and safe treatment solutions while prioritizing the needs and well-being of patients. With a strong corporate philosophy grounded in research and development, Sensorion SA strives to address the unmet medical needs in the field of auditory disorders, aiming to make a meaningful impact on the lives of individuals affected by these conditions.
Analisten hanteren momenteel een gemiddeld koersdoel van 2,42 EUR voor het aandeel Sensorion (mediaan: 2,30 EUR), oftewel -73,6 % ten opzichte van de laatste koers. De consensus is gebaseerd op 13 analistenratings.
14 analisten beoordelen het aandeel Sensorion momenteel: 13 adviseren kopen, 1 houden en 0 verkopen. Voor 2026 verwachten analisten dat Sensorion een omzet van 4,55 Miljoen EUR en winst per aandeel van -169,83 EUR behaalt.
Het aandeel Sensorion (ALSEN.PA) is genoteerd aan 5 beurzen, waaronder: Frankfurt (RFM.F), München (RFM.MU), Düsseldorf (RFM.DU), Paris (ALSEN.PA).
Sensorion SA is a French biotechnology company specializing in the development of novel therapies for the treatment of inner ear disorders and hearing loss. The company focuses on researching and developing drugs tailored to the specific needs of patients. Sensorion aims to create innovative products and therapies in the field of otolaryngology to meet the needs of patients.
De verwachte omzet van Sensorion bedraagt 4,55 Miljoen EUR. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Sensorion bedraagt -1,02 Miljard EUR. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Sensorion bedraagt momenteel -0,05. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Sensorion-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Sensorion bedraagt momenteel 12,23. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Sensorion-aandeel.
De Eulerpool Kwaliteitsscore voor Sensorion is 4/10.
De ISIN van Sensorion is FR0012596468. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Sensorion is A14SVV. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Sensorion is ALSEN.PA. Onder dit beurstickersymbool wordt het Sensorion-aandeel op de beurs verhandeld.
Sensorion aandeel
Sensorion Peer Group
Sensorion Ticker
Sensorion FIGI
Alle fundamentals en diepgaande analyse van Sensorion
Onze aandelenanalyse van het Sensorion-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Sensorion. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: